GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/HCC/Nutrition in Hepatocellular Carcinoma - J of JGH - Jan,26

Nutrition in Hepatocellular Carcinoma - J of JGH - Jan,26

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2026

Quick Answer

The topic of nutrition in hepatocellular carcinoma (HCC) is highly relevant and extensively studied due to the profound impact of malnutrition on patient outcomes. While I cannot access specific articles such as "Nutrition in Hepatocellular Carcinoma - J of JGH - Jan, 26," I can provide a detailed overview based on the context and current knowledge related to nutrition in HCC.


The topic of nutrition in hepatocellular carcinoma (HCC) is highly relevant and extensively studied due to the profound impact of malnutrition on patient outcomes. While I cannot access specific articles such as "Nutrition in Hepatocellular Carcinoma - J of JGH - Jan, 26," I can provide a detailed overview based on the context and current knowledge related to nutrition in HCC.

**Overview of Nutrition in Hepatocellular Carcinoma (HCC):**

1. **Prevalence of Malnutrition**:

  • Malnutrition is exceedingly common in patients with HCC, significantly contributing to morbidity, mortality, and poor clinical outcomes.
  • Unlike other cancers, malnutrition in HCC often begins early in the disease course due to the compounding effects of chronic liver disease.

2. **Drivers of Nutritional Decline**:

  • **Hepatic Dysfunction**: Chronic liver disease and cirrhosis associated with HCC disrupt carbohydrate, protein, and lipid metabolism, leading to a hypercatabolic state.
  • **Insulin Resistance**: Impaired glycogen storage and early gluconeogenesis result in muscle breakdown and energy imbalance.
  • **Protein Catabolism**: Negative nitrogen balance and preferential skeletal muscle degradation accelerate sarcopenia.
  • **Impaired Fat Absorption**: Cholestasis and reduced bile acid synthesis hinder fat absorption, resulting in energy deficits and fat-soluble vitamin deficiencies.
  • **Micronutrient Deficiencies**: Vitamins A, D, E, K, and trace element deficiencies contribute to complications like coagulopathy, bone disease, and neuromuscular dysfunction.

3. **Key Features of Malnutrition in HCC**:

  • **Sarcopenia**: Loss of skeletal muscle mass is a hallmark feature in HCC patients and independently predicts poorer survival, higher complication rates, and reduced tolerance to treatments.
  • **Cachexia**: Chronic systemic inflammation drives anorexia, hypermetabolism, and cancer-related cachexia, further worsening nutritional status.
  • **High Energy Expenditure**: Many patients with HCC exhibit increased resting energy expenditure, exacerbating the gap between nutritional intake and metabolic demands.

4. **Prognostic Implications**:

  • Malnutrition and sarcopenia are strongly associated with reduced overall survival, increased recurrence rates, and higher postoperative risks.
  • Addressing nutritional deficits early and comprehensively can improve clinical outcomes.

5. **Assessment of Nutritional Status**:

  • **Validated Screening Tools**: Tools such as NRS-2002, MUST, PG-SGA, and GLIM are essential for identifying patients at nutritional risk.
  • **Muscle Mass Evaluation**: CT imaging at the L3 vertebra is a gold-standard method for assessing skeletal muscle mass.
  • **Functional Status**: Handgrip strength provides a practical measure of muscle function and complements structural assessments.
  • **Limitations of Laboratory Markers**: Serum albumin and prealbumin are unreliable indicators due to hepatic dysfunction and systemic inflammation.

6. **Nutritional Management**:

  • **Individualized Targets**: Energy and protein requirements should be tailored to the disease stage, severity of cirrhosis, and treatment modalities.
  • **Oral Nutritional Supplements**: Supplements enriched with branched-chain amino acids are beneficial for maintaining protein balance and improving clinical outcomes.
  • **Enteral Nutrition**: Preferred over parenteral nutrition if gastrointestinal function is preserved.
  • **Exercise**: Resistance and aerobic exercise programs help mitigate sarcopenia and functional decline when integrated with nutritional support.
  • **Multidisciplinary Care**: Coordinated care involving hepatologists, oncologists, dietitians, and physiotherapists is essential for optimal management.

7. **Emerging Research and Guidelines**:

  • The field continues to evolve with ongoing research into the role of specific nutrients, exercise regimens, and novel interventions to address malnutrition and sarcopenia in HCC.
  • Journals like the "Journal of Gastroenterology and Hepatology" (JGH) often publish cutting-edge studies and guidelines on this topic.

If you are looking for specific insights or findings from the January 26 article in JGH, I recommend accessing the journal directly through medical databases such as PubMed, Wiley Online Library, or institutional subscriptions. Let me know if you'd like guidance on how to access such resources!

Related Q&A

Liver Stiffness for HCC Risk in MASLD: Hepatology | July 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools are needed to identify high-risk patients who...

Durvalumab Plus Tremelimumab in Real-World HCC: JGH | May 2026

Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility criteria of clinical trials. This multicenter study...

ALBI Grade and Sarcopenia in Unresectable HCC: IJG | July 2026

Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of ALBI grade, EZ-ALBI grade, and sarcopenia in...

HCC Surveillance Saves Lives: Frontline Gastroenterology | July 2026

Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway. Why was...

Yttrium-90 Radioembolization for HCC: The Lancet Regional Health | July 2026

Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety,...

Bleeding Risk with Immunotherapy in Advanced HCC: JHEP Reports | July 2026

Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients with underlying cirrhosis and portal hypertension. Why...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer